Vaxart (VXRT) Competitors $0.71 +0.01 (+1.21%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.74 +0.02 (+3.01%) As of 02/21/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VXRT vs. RLAY, TYRA, ANAB, KURA, CRMD, ABUS, PHAR, IMTX, ORIC, and RAPPShould you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include Relay Therapeutics (RLAY), Tyra Biosciences (TYRA), AnaptysBio (ANAB), Kura Oncology (KURA), CorMedix (CRMD), Arbutus Biopharma (ABUS), Pharming Group (PHAR), Immatics (IMTX), ORIC Pharmaceuticals (ORIC), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry. Vaxart vs. Relay Therapeutics Tyra Biosciences AnaptysBio Kura Oncology CorMedix Arbutus Biopharma Pharming Group Immatics ORIC Pharmaceuticals Rapport Therapeutics Relay Therapeutics (NASDAQ:RLAY) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends. Which has higher valuation and earnings, RLAY or VXRT? Vaxart has lower revenue, but higher earnings than Relay Therapeutics. Vaxart is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$25.55M25.98-$341.97M-$2.61-1.52Vaxart$7.38M22.50-$82.46M-$0.41-1.78 Do analysts recommend RLAY or VXRT? Relay Therapeutics currently has a consensus price target of $20.50, suggesting a potential upside of 417.02%. Vaxart has a consensus price target of $4.00, suggesting a potential upside of 447.95%. Given Vaxart's stronger consensus rating and higher probable upside, analysts clearly believe Vaxart is more favorable than Relay Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91Vaxart 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is RLAY or VXRT more profitable? Relay Therapeutics has a net margin of 0.00% compared to Vaxart's net margin of -431.61%. Relay Therapeutics' return on equity of -45.75% beat Vaxart's return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -45.75% -40.75% Vaxart -431.61%-110.46%-62.78% Does the MarketBeat Community favor RLAY or VXRT? Vaxart received 251 more outperform votes than Relay Therapeutics when rated by MarketBeat users. However, 69.41% of users gave Relay Therapeutics an outperform vote while only 65.54% of users gave Vaxart an outperform vote. CompanyUnderperformOutperformRelay TherapeuticsOutperform Votes5969.41% Underperform Votes2630.59% VaxartOutperform Votes31065.54% Underperform Votes16334.46% Does the media favor RLAY or VXRT? In the previous week, Relay Therapeutics had 4 more articles in the media than Vaxart. MarketBeat recorded 4 mentions for Relay Therapeutics and 0 mentions for Vaxart. Relay Therapeutics' average media sentiment score of 1.07 beat Vaxart's score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Relay Therapeutics Positive Vaxart Neutral Which has more risk and volatility, RLAY or VXRT? Relay Therapeutics has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Do institutionals and insiders hold more shares of RLAY or VXRT? 97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 18.1% of Vaxart shares are owned by institutional investors. 4.3% of Relay Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryRelay Therapeutics beats Vaxart on 13 of the 18 factors compared between the two stocks. Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VXRT vs. The Competition Export to ExcelMetricVaxartBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$166.52M$3.12B$5.80B$8.99BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-1.7929.7726.3218.88Price / Sales22.50322.52452.0876.91Price / CashN/A183.5344.0437.47Price / Book1.923.577.644.66Net Income-$82.46M-$71.72M$3.18B$245.69M7 Day Performance-2.17%-2.14%-1.66%-2.22%1 Month Performance-4.51%0.60%0.41%-1.95%1 Year Performance-48.23%-11.08%17.47%14.12% Vaxart Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VXRTVaxart1.6943 of 5 stars$0.71+1.2%$4.00+460.6%-49.4%$162.31M$7.38M-1.74120RLAYRelay Therapeutics2.2853 of 5 stars$4.00+1.0%$20.50+412.5%-62.6%$669.52M$25.55M-1.53330Positive NewsTYRATyra Biosciences1.7637 of 5 stars$13.19+7.7%$30.50+131.2%-31.5%$667.45MN/A-8.1920Analyst ForecastANABAnaptysBio3.7756 of 5 stars$21.22+10.0%$37.45+76.5%-27.0%$645.73M$17.16M-3.49100High Trading VolumeKURAKura Oncology4.3925 of 5 stars$8.28flat$27.13+227.6%-58.7%$643.85MN/A-3.51130CRMDCorMedix1.2114 of 5 stars$10.48+0.4%$15.67+49.5%+211.7%$635.93M$60,000.00-12.9430News CoverageABUSArbutus Biopharma1.6567 of 5 stars$3.29-0.3%$5.50+67.2%+18.9%$623.42M$18.14M-7.6590PHARPharming Group2.925 of 5 stars$9.13+3.2%$27.00+195.7%-19.7%$621.19M$285.75M-35.12280Positive NewsGap UpIMTXImmatics1.599 of 5 stars$5.05-0.8%$16.67+230.0%-61.7%$602.77M$58.44M-7.65260ORICORIC Pharmaceuticals4.5379 of 5 stars$8.36+1.1%$18.71+123.9%-25.6%$589.97MN/A-4.6480Earnings ReportAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeRAPPRapport Therapeutics1.6432 of 5 stars$15.90+0.8%$35.00+120.1%N/A$581.62MN/A0.00N/A Related Companies and Tools Related Companies Relay Therapeutics Competitors Tyra Biosciences Competitors AnaptysBio Competitors Kura Oncology Competitors CorMedix Competitors Arbutus Biopharma Competitors Pharming Group Competitors Immatics Competitors ORIC Pharmaceuticals Competitors Rapport Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VXRT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
